ArticleActa neurologica Belgica2026
Not all cancers are equal: uneven access to glioma clinical trials in Europe.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGliomas are rare, aggressive CNS tumors with poor prognosis, and clinical trials are essential for access to novel therapies. We assessed cross-country disparities in glioma trial activity within the WHO European Region and compared patterns with lung cancer trials.
methodsWe performed a cross-sectional search of ClinicalTrials.gov for glioma trials involving WHO European Region countries. Eight countries representing contrasting trial patterns were analyzed (France, Germany, Italy, Denmark, Poland, Hungary, Greece, Turkey). Trial access was standardized by estimated annual incident cases using country-specific incidence rates and population. Lung cancer trials were analyzed in parallel. Temporal trends and associations with gross national income (GNI) per capita and human development index (HDI) were also evaluated.
resultsOf 3,292 glioma trials registered globally, 1,058 involved at least one WHO European Region country; 640 included at least one selected country. France, Germany, and Italy had the highest trial volume and growth since 2004, whereas Turkey, Hungary, and Greece remained consistently low. After adjustment for estimated annual glioma cases, Denmark, France, and Germany showed the highest trial access. Glioma trial access correlated with GNI per capita (ρ = 0.76, p = 0.028) but not with HDI (ρ = 0.69, p = 0.058). Lung cancer trials were more numerous and showed no association with GNI per capita or HDI. Several countries demonstrated marked discordance, with minimal glioma trial activity despite considerable lung cancer trial volumes.
conclusionGlioma clinical trial access across Europe is highly uneven in contrast to lung cancer trials. Targeted capacity-building strategies to promote equitable access to glioma research is needed.
Indexed as
Identifiers
42176152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.